Nedaplatin: a new paradigm in nasopharyngeal cancer

Radiotherapy concurrent with cisplatin either weekly or every 3 weeks’ regimen has been accepted as the standard of care for locoregional advanced stage of nasopharyngeal cancer for decades (1-5). Although it has shown a statistically significant benefit in terms of locoregional control and survival rate when compared with radiotherapy alone, but severe acute and late toxicities might affect the quality of life (QoL), mainly nausea, vomiting, impaired renal function, and hearing toxicity (6-9).